SRP4639
BMP-13 human
recombinant, expressed in E. coli, ≥95% (SDS-PAGE)
Manufacturer: Sigma Aldrich
Synonym(S): CDMP-2, Cartilage-Derived Morphogenetic Protein-2, GDF-6, bone morphogenetic protein 13
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 50 μG | SRP4639-50-μG | In Stock | ₹ 34,943.10 |
SRP4639 - 50 μG
In Stock
Quantity
1
Base Price: ₹ 34,943.10
GST (18%): ₹ 6,289.758
Total Price: ₹ 41,232.858
biological source
human
recombinant
expressed in E. coli
Assay
≥95% (SDS-PAGE)
form
lyophilized
potency
0.5-4 μg/mL ED50 (determined by its ability to induce alkaline phosphatase production by ATDC-5 chondrogenic cells.)
mol wt
~27 kDa
packaging
pkg of 50 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
NCBI accession no.
Q6KF10
Related Products
Description
- General description: BMPs (bone morphogenetic proteins) belong to the TGF-β superfamily of structurally related signaling proteins. These ligands mediate numerous physiological processes. BMPs initiate, promote and maintain cartilage and bone development, growth, remodeling and repair, in both prenatal development and postnatal growth of eye, heart, kidney, skin, and other tissues. Expression of BMP-13 has been found in the hypertrophic chondrocytes of ossifying long bone centers. Recombinant human BMP-13/CDMP-2 is a 27 kDa homodimeric disulfide-linked protein consisting of two 120 amino acids polypeptide chains.
- Physical form: Sterile filtered and Lyophilized without additives.
- Reconstitution: Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
Compare Similar Items
Show Difference
biological source: human
recombinant: expressed in E. coli
Assay: ≥95% (SDS-PAGE)
form: lyophilized
potency: 0.5-4 μg/mL ED50 (determined by its ability to induce alkaline phosphatase production by ATDC-5 chondrogenic cells.)
mol wt: ~27 kDa
packaging: pkg of 50 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: Q6KF10
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥95% (SDS-PAGE)
form:
lyophilized
potency:
0.5-4 μg/mL ED50 (determined by its ability to induce alkaline phosphatase production by ATDC-5 chondrogenic cells.)
mol wt:
~27 kDa
packaging:
pkg of 50 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
Q6KF10
biological source: human
recombinant: expressed in E. coli
Assay: ≥98% (HPLC)≥98% (SDS-PAGE)
form: lyophilized
potency: __
mol wt: ~15.4 kDa
packaging: pkg of 50 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: P47929
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥98% (HPLC)≥98% (SDS-PAGE)
form:
lyophilized
potency:
__
mol wt:
~15.4 kDa
packaging:
pkg of 50 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
P47929
biological source: human
recombinant: expressed in E. coli
Assay: ≥95% (HPLC)≥95% (SDS-PAGE)
form: lyophilized
potency: 501.0-2.0 μg/mL ED50
mol wt: ~11.2 kDa
packaging: pkg of 20 μg
storage condition: __
impurities: endotoxin, tested
NCBI accession no.: NM_001901
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥95% (HPLC)≥95% (SDS-PAGE)
form:
lyophilized
potency:
501.0-2.0 μg/mL ED50
mol wt:
~11.2 kDa
packaging:
pkg of 20 μg
storage condition:
__
impurities:
endotoxin, tested
NCBI accession no.:
NM_001901
biological source: human
recombinant: expressed in E. coli
Assay: ≥95% (HPLC)≥95% (SDS-PAGE)
form: lyophilized
potency: __
mol wt: ~29.7 kDa
packaging: pkg of 25 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: AAD30179
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥95% (HPLC)≥95% (SDS-PAGE)
form:
lyophilized
potency:
__
mol wt:
~29.7 kDa
packaging:
pkg of 25 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
AAD30179